4
Changes in Ownership
Taysha Gene Therapies, Inc. Filed Acc 0001415889-25-024369
President and Head of R&D sold 200,000 shares at $3.23 ($646,000)
- President and Head of R&D acquired 41,150 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar President and Head of R&D | 2025-09-10 | Option exercise 10b5-1 | +41,150 | $0.70 | $28,760 | 1,206,439 | D |
| Nagendran Sukumar President and Head of R&D | 2025-09-10 | Sale 10b5-1 | −200,000 | $3.23 | $646,000 | 1,006,439 | D |
| Derivatives | |||||||
| Nagendran Sukumar President and Head of R&D | 2025-09-10 | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −41,150 | 292,855 | D | ||
| Open-market sales · 200,000 sh · avg $3.23 · $646,000 | |||||||
Loading xslF345X05/form4-09122025_040917.xml…